COMPANY RESEARCHSamsung Biologics offers Biologics identity, purity, potency, release and stability testing. This is the analytical service business of an integrated CRO/CDMO.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Offers mRNA drug substance and drug product services, including process development, analysis, and product characterization. Each site's project scope requires confirmation.
Biologics CDO services include cell line, process, analytical, and drug product formulation development, with a disclosed high-concentration formulation platform.
Biologics identity, purity, potency, release and stability testing
Integrated CRO/CDMO analytical services
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| RNA / LNP service capabilities | Project-dependent / not verified · Project-dependent / not verified | Services / platform | This record does not establish human validation of the entire platform |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Samsung Biologics reported that 97.66% of PolyPeptide's issued shares had been tendered by October 30, with a provisional participation rate of 97.99% including concert parties. Its November 2 notice postponed settlement and anticipated completion in late 2026 or the first quarter of 2027, subject to remaining offer conditions and regulatory approvals.
Japanese researchers evaluated crushed tadalafil tablets mixed with lactose at 40 mg/g during 90 days at 25°C under defined humidity and lighting conditions. Thermal analysis and powder X-ray diffraction showed no appreciable changes in thermal behavior or crystalline state. The findings concern the tested preparation and conditions; they do not establish clinical equivalence or a general storage period for other formulations.
A Nature study delivered guide RNA and base-editor mRNA in GalNAc lipid nanoparticles to inactivate liver ANGPTL3. Nonhuman primates showed mean ANGPTL3 protein reductions exceeding 90%, with durability assessed through three years after one dose. Lipid reductions were observed in animal models. Human liver-cell testing assessed selected off-target sites; the paper does not report human clinical efficacy.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.